



FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP
600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701-3271
WWW.FULBRIGHT.COM

STEVEN L. HIGHLANDER
PARTNER
SHIGHLANDER@FULBRIGHT.COM

DIRECT DIAL: (512) 536-3184
TELEPHONE: (512) 474-5201
FACSIMILE: (512) 536-4598

March 8, 2004

CERTIFICATE OF MAILING
37 C.F.R 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: MS DD, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date below:

March 8, 2004

Date

Steven L. Highlander

MS DD

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RE: *U.S. Patent Application No. 10/760,111 "METHODS AND COMPOSITIONS RELATING TO MUSCLE SPECIFIC SARCOMERIC CALCINEURIN-BINDING PROTEINS (CALSARCINS)" – Eric Olson and Norbert Frey*
Our Reference: UTSD:729USD1

Sir :

Enclosed for filing in the above-referenced patent application is an Information Disclosure Statement and Form PTO-1449.

No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/UTSD:729USD1.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,

Steve L. Highlander
Reg. No. 37,642

SLH/cas
Encl.: As noted

25384040.1

PATENT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

The Application of:
Eric N. Olson and Norbert Frey

Serial No.: 10/760,111

Filed: January 16, 2004

For: METHODS AND COMPOSITIONS
RELATING TO MUSCLE SPECIFIC
SARCOMERIC CALCINEURIN-
BINDING PROTEINS (CALSARCINS)

Group Art Unit: Unknown

Examiner: Unknown

Atty. Dkt. No.: UTSD:729USD1

CERTIFICATE OF MAILING 37 C.F.R 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: MS DD, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:	
March 8, 2004	_____ Date Steven L. Highlander

INFORMATION DISCLOSURE STATEMENT

MS DD
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:


In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record.

In accordance with 37 C.F.R. §§ 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/UTSD:729USD1.


This application is a divisional application of Serial No. 10/045,594, filed November 7, 2001 and is relied upon for an earlier filing date under 35 U.S.C. § 120. In accordance with Rule 37 C.F.R. § 1.98(d) copies of the listed documents are not enclosed as they have been previously cited by or submitted to the Patent and Trademark Office in prior application Serial No. 10/045,594.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,

Steven L. Highlander
Reg. No. 37,642
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: March 8, 2004



Form PTO-1449 (modified) List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Atty. Docket No. UTSD:729USD1	Serial No. 10/760,111
		Applicant Eric Olson Norbert Frey	
		Filing Date: January 16, 2004	Group: Unknown
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B1	WO 96 12806 A	5-2-96	PCT			
	B2	WO 99 19473 A	4-22-99	PCT			
	B3	WO 01 53312 A	7-26-01	PCT			
	B4	WO 01 92567 A	12-6-01	PCT			
	B5	WO 02 04491 A	1-17-02	PCT			

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Ahmad et al., "Homo sapiens muscle-specific protein (C4 or C5)," Abstract, DATABASE EMBL 'Online!, Database Accession No. AF249873, 2000.
	C2	Ahmad et al., "Identification and characterization of a novel gene (C4orf5) located on human chromosome 4q with specific expression in cardiac and skeletal muscle," <i>Genomics</i> , 70:347-353, 2000.
	C3	Alignment of SEQ. ID NO.2 with SEQ. ID NO.286 of USSN 10/098841, PGPUB NO. 210020197679A1.
	C4	Ding et al., "Pressure overload induces severe hypertrophy in mice treated with cyclosporine, an inhibitor of calcineurin," <i>Circ Res.</i> , 84(6):729-734, 1999.
	C5	Faulkner et al., "FATZ: a filamin, actinin, and telethonin binding protein of the Z-disk of skeletal muscle," <i>Journ. Bio. Chem.</i> , 275:41234-41242, 2000.

25384004.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)

Atty. Docket No.

Serial No.

UTSD:729USD1

10/760,111

Applicant

Eric Olson

Norbert Frey

Filing Date:

January 16, 2004

Group:

Unknown

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C6	Frey et al., "Calsarcins, a novel family of sarcomeric calcineurin-binding proteins," <i>Proc. Natl. Acad. Sci. USA</i> , 97:14632-14637, 2000.
	C7	Fuentes et al, "DSCR1, overexpressed in Down syndrome, is an inhibitor of calcineurin-mediated signaling pathways," <i>Human Mol. Gen.</i> , Oxford University Press, U.K., 9:1681-1690, 2000.
	C8	Hill et al., "Cardiac hypertrophy is not a required compensatory response to short-term pressure overload," <i>Circulation</i> , 101(24):2863-2869, 2000.
	C9	Ievolella, "Homo sapiens mRNA for FATZ related protein 2 (ORF1)," Abstract, DATABASE EMBL 'Online!', EBI Database Acession No. AJ252149, 2000.
	C10	Lim et al., "Calcineurin expression, activation, and function in cardiac pressure-overload hypertrophy," <i>Circulation</i> , 101(20):2431-2437, 2000.
	C11	Lim et al., "Reversal of cardiac hypertrophy in transgenic disease models by calcineurin inhibition," <i>J Mol Cell Cardiol</i> , 32(4):697-709, 2000.
	C12	Marban et al., "Intracellular free calcium concentration measured with 19F NMR spectroscopy in intact ferret hearts," <i>Proc Natl Acad Sci U S A</i> , 84:6005-6009, 1987.
	C13	Molkentin et al, "A calcineurin-dependent transcriptional pathway for cardiac hypertrophy," <i>Cell</i> , 93:215-228, 1998.
	C14	Rothermel et al, "A protein encoded within the Down syndrome critical region is enriched in striated muscles and inhibits calcineurin signaling," <i>J. Bio. Chem.</i> , 275:8719-8725, 2000.
	C15	Seidman and Seidman, "Molecular genetic studies of familial hypertrophic cardiomyopathy," <i>Basic Res Cardiol.</i> ;93 Suppl 3:13-16, 1998.
	C16	Shimoyama et al., "Calcineurin plays a critical role in pressure overload-induced cardiac hypertrophy," <i>Circulation</i> , 100(24):2449-2454, 1999.
	C17	Sussman et al., "Prevention of cardiac hypertrophy in mice by calcineurin inhibition," <i>Science</i> , 281:1690-1693, 1998.
	C18	Zhang et al., "Failure of calcineurin inhibitors to prevent pressure-overload left ventricular hypertrophy in rats," <i>Circ Res.</i> , 84(6):722-728, 1999.
	C19	GenBank accession number AA036142

25384004.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)

Atty. Docket No.

Serial No.

UTSD:729USD1

10/760,111

Applicant

Eric Olson

Norbert Frey

Filing Date:

January 16, 2004

Group:

Unknown

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

*See Page 1***Other Art (Including Author, Title, Date Pertinent Pages, Etc.)**

Exam. Init.	Ref. Des.	Citation
	C20	GenBank accession number AA176945
	C21	GenBank accession number AA197193
	C22	GenBank accession number W29466
	C23	GenBank accession number AC008453.3
	C24	GenBank accession number AW000988
	C25	GenBank accession number AW742494
	C26	GenBank accession number AW964108

25384004.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.